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The expression of Nuclear Protein 1 (NUPR1) is associated with chemoresistance in multiple malig-
nancies. We previously reported that NUPR1 functions as a transcriptional cofactor for the p300–p53
complex and transcriptionally regulates p21 expression. In the present study we investigated the
activity of NUPR1 in p53-deﬁcient, triple-negative, inﬂammatory SUM159 breast cancer cells. Our
studies reveal that NUPR1 confers growth beneﬁt and chemoresistance by causing Akt-mediated
phosphorylation and subsequent cytoplasmic re-localization of p21 and activation of the anti-apop-
totic Bcl-xL protein. Our ﬁndings elucidate a NUPR1-PI-3-K/Akt-phospho-p21 axis that functions in
p53-negative, inﬂammatory breast cancer cells to enhance chemoresistance in breast cancer.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Recent studies show that p21 can act both as a tumor suppressorMuch progress has been made in the treatment of breast cancer,
but in metastatic disease chemoresistance remains a barrier to
long-term survival. A number of clinical trials have demonstrated
that complete response occurs in only one-third of patients with
recurrent breast cancer [1,2]. Hence, there is an urgent need to
identify molecular mechanisms that regulate chemoresistance.
Nuclear Protein 1 (NUPR1, also known as com1 and p8) is a
small molecule whose levels are upregulated in response to cellu-
lar stress and also in multiple malignancies [3–7] and are inversely
correlated with apoptosis and autophagy [8]. We and others have
shown that NUPR1 confers resistance to multiple drugs, including
gemcitabine, paclitaxel and doxorubicin [9]. NUPR1 plays a role in
tumor progression and distant metastasis of breast cancer [10] and
is shown to regulate many steps in metastasis, including migration,
invasion, and adhesion [11].
We have reported that NUPR1 mediates doxorubicin resistance
in a p53-dependent manner by transcriptionally upregulating p21
[9]. p21 is awell-knownnegative regulator of cell cycle progression.chemical Societies. Published by E
f Pathology, University of
rmingham, AL 35233, Unitedgene and an oncogene depending on its cellular localization.
Whereas the growth inhibitory functions of p21 are associated with
its nuclear localization, the anti-apoptotic or oncogenic activities
are frequently associated with its cytoplasmic accumulation
[12,13]. When p21 is localized to the nucleus it arrests cell growth
by inhibiting cyclin dependent kinases [14], and also by inhibiting
DNA synthesis through interactions with proliferating cell nuclear
antigen, PCNA [15]. In contrast, in the cytoplasm, p21 complexes
with and inactivates Apoptosis Signaling Kinase 1 (ASK1) [12,16],
resulting in the activation of anti-apoptotic BCL-2 [17].
Our investigations have revealed that in SUM159, p53-null, tri-
ple-negative, inﬂammatory breast cancer cells [18] NUPR1-driven
signaling activates PI3K/AKT signaling and causes p21 to be local-
ized to the cytoplasm thereby resulting in hypo-phosphorylated
Bcl-xL,increased cell proliferation and subsequent chemoresistance
to doxorubicin.
2. Materials and methods
2.1. Cell lines, expression constructs and transfection
SUM159 cells and MCF10AT cells were cultured as previously
described [19]. Human NUPR1 cDNA was cloned in pcDNA3.1(+)lsevier B.V. All rights reserved.
3430 A.J. Vincent et al. / FEBS Letters 586 (2012) 3429–3434by PCR ampliﬁcation of the gene from pEF6/V5-His(p8). SUM159
cells, obtained from Asterand Inc., were transfected using Lipofect-
amine 2000 (Invitrogen, Carlsbad, CA) per manufacturer’s speciﬁ-
cations. Stable transfectants were validated by real-time qRT-PCR
and western blotting. Endogenous NUPR1 fromMCF10AT cells (ob-
tained from the Karmanos Cancer Center) was silenced using
shRNA (Oligoengine, Seattle, WA). NUPR1 knockdown stable cells
were selected in 250 ng/ml puromycin. Stable transfectants were
derived from cell cultures with less than 10 passages in order to
minimize the possible impact of clonal diversiﬁcation and pheno-
typic instability in vitro.
2.2. Real-time quantitative PCR of tissue array
TissueScan plates (Origene, Rockville, MD) were assessed for the
expression of NUPR1 transcripts using the manufacturer’s protocol.
The reaction was carried out in a Bio-Rad iCycler iQ5 using the fol-
lowing program: activation step of 50 C for 2 min, then 42 cycles
of 95 C for 5 min, 95 C for 15 s, and 60 C for 1 min. Data was ex-
pressed as dCT (difference in Ct between Ct values of NUPR1 and b-
actin). A 5% level of signiﬁcance was used to determine signiﬁcance
of results.
2.3. Chemicals and antibodies
Antibodies used in this study include p21 (Cell Signaling Tech-
nology, Danvers, MA), phospho-Thr145 p21 (Santa Cruz Biotech-
nology, Santa Cruz, CA), phospho-Ser146 p21 (Santa Cruz),
GAPDH (Cell Signaling), horseradish peroxidase linked beta-actin
(Abcam, Cambridge, MA), phospho-Ser473-Akt (Cell Signaling),
pan-Akt (Cell Signaling), BCL-xL (Cell Signaling), phospho-Ser62
BCL-xL (abcam), ECL™ sheep anti-mouse IgG HRP linked (GE
Healthcare UK, Limited, Amersham, Buckinghamshire, UK), ECL™
donkey anti-rabbit IgG HRP linked (GE Healthcare UK, Limited),
donkey anti-goat IgG HRP linked (Santa Cruz), and Alexa Fluor
488 Goat anti-rabbit (Invitrogen). Small molecule inhibitors used
include Wortmannin to inhibit PI-3 Kinase and, Akt Inhibitor IV
(Calbiochem) to inhibit Akt (IC50<1.25 lM).3. Immunocytochemistry
Cells were plated on Thomas Red Label MICRO Cover Glasses
(Thomas Scientiﬁc, Swedesboro, NJ), and treated as indicated. Cells
were ﬁxed and permeabilized with methanol at 20 C for 5 min,
blocked in 10% normal goat serum in PBS, and stained with
1:200 rabbit anti-p21 overnight at 4 C. Cells were washed in
PBS, and treated with 1:200 Alexa Fluor 488 Goat anti-rabbit at
room temperature for 1 h. The cells were mounted in VECTA-
SHIELD with propidium iodide (Vector Laboratories, Inc, Burlin-
game, CA), imaged on a Nikon Eclipse TE-2000U microscope
(Nikon Instruments Inc, Melville, NY). We estimated 10 ﬁelds per
image for quantitation.
4. Results
4.1. NUPR1 modulates chemoresistance and cellular localization of p21
We probed an array comprising cDNA derived from normal
breast tissue and breast tumor tissue for the expression of NUPR1.
The levels of NUPR1 were upregulated (p < 0.05) in breast tumor
tissue relative to normal breast tissue (Fig. 1A). In order to under-
stand the role of NUPR1 in modulating the chemoresponsiveness of
breast tumor cells, we worked with two systems: SUM159 cells
were genetically engineered to constitutively express NUPR1 and
the endogenous NUPR1 in MCF10AT cells was abrogated by RNAinterference. We chose to overexpress NUPR1 in SUM159 cells in
order to model the ability of NUPR1 to aid in disease progression
by increasing chemoresistance in this already pathologic cell line.
On the other hand, we chose to abrogate the expression of NUPR1
in MCF10AT cells to provide evidence for NUPR1’s physiologic abil-
ity to protect breast epithelial cells from stress, including chemo-
therapeutic induced stress.
Stable expression of NUPR1 in SUM159 cells resulted in upreg-
ulation of p21 to a small extent (Fig. 1B and Supplementary
Fig. 1A). Interestingly, p21 in the NUPR1-expressing cells was
localized to the cytoplasmic compartment (Fig. 1C and Supplemen-
tary Fig. 1B). The upregulation of NUPR1 achieved in these cells is
6-fold, comparable to the physiological upregulation in NUPR1
levels that occur when cells are treated with stressors such as
TNF, ceramide, staurosporine or LPS [20,21]. In agreement with
our previous reports, NUPR1 expression allowed the cells to resist
the cytotoxic effects of doxorubicin (Fig. 1D; Supplementary
Fig. 1C). In contrast, MCF10AT cells that were engineered for stable
silencing of endogenous NUPR1 (Fig. 1E) showed enhanced cyto-
toxicity in response to doxorubicin (Fig. 1F) and taxol (Supplemen-
tary Fig. 1D). While the vector control cells showed diffuse
distribution of p21, in the NUPR1-silenced cells, p21 was localized
predominantly in the nucleus (Fig. 1G and Supplementary
Fig. 2).Thus, modulating NUPR1 expression in cells altered the
sub-cellular localization of p21.
4.2. PI-3-K/Akt signaling mediates the cytoplasmic localization of p21
in NUPR1-expressing cells
While nuclear p21 executes a tumor suppressive function, cyto-
plasmic p21 functions in an anti-apoptotic role and enhances cell
survival. The mechanisms that regulate the cytoplasmic localiza-
tion of p21 have been mainly attributed to the phosphorylation
of consensus sites Thr145 and/or Ser146 within the nuclear local-
ization signal (NLS) of p21 [22–24]. The Protein Kinase B/Akt path-
way is attributed to cause phosphorylation of p21 at its NLS
resulting in cytoplasmic localization of p21 [22,25,26]. Besides
Akt, IjB kinase b (IKKb) has also been reported to bring about cyto-
plasmic localization of p21 [27]. IKKb activity also causes phos-
phorylation of Akt [27] and subsequent cytoplasmic p21
accumulation. IKKb is one of the two catalytic subunits of the
IKK complex. Upon activation by cytokines, the IKK complex,
mainly IKKb, signals to activate the transcription factor, NF-jB.
IKKb activity also causes phosphorylation of Akt [27] and subse-
quent cytoplasmic p21 accumulation.
To determine the mechanism(s) that lead to NUPR1-mediated
altered localization of p21, we assessed the impact of an Akt inhib-
itor (Akt Inhibitor IV), a PI-3 -kinase inhibitor (wortmannin) and an
IKK inhibitor (BMS-345541) on NUPR1-expressing cells and control
cells and performed immunoﬂuorescent microscopy to visualize
the impact on sub-cellular localization of p21. NUPR1 overexpres-
sion corresponded to nuclear exclusion of p21 with a resultant
cytoplasmic localization of p21. In contrast, control cells displayed
predominantly nuclear p21 staining. While Akt Inhibitor IV and
Wortmannin reversed the NUPR1-mediated cytoplasmic-localiza-
tion of p21, the IKK inhibitor was only partially effective at restor-
ing the nuclear localization of p21 (Fig. 2).
4.3. NUPR1 expression results in Akt-mediated phosphorylation of p21
In order to determine if speciﬁc post-translational modiﬁca-
tions of p21 result from the expression of signaling initiated by
NUPR1, we assessed the NUPR1-expressing and vector control cells
for their status of Akt and p21. As seen in Fig. 3A, while NUPR1
expression results in an overall increase in the levels of Akt, there
is also a distinct increase in the levels of activated p-Ser-473-Akt
Fig. 1. NUPR1 modulates p21 localization and chemoresponsiveness of breast cancer cells. (A) NUPR1 transcript levels are upregulated in breast tumor tissues relative to
normal breast tissue (⁄p = 0.03). (B) Stable transfectants (clones 15 and 37) of SUM159 cells expressing NUPR1 were generated. Cell lysates were resolved by SDS-PAGE and
immunoblotted. NUPR1-expresing cells show minimal changes in the levels of p21. b-Actin serves as a loading control. UT: Untransfected cells; EV: empty vector
transfectants. (C) NUPR1 expression in SUM159 cells causes p21 to be predominantly localized to the cytoplasm. The cells were stained for p21 (FITC) and DAPI and assessed
microscopically for p21 localization by immunocytochemistry. (D) NUPR1 expression makes SUM159 cells resistant (⁄p < 0.05) to doxorubicin. Cells were treated with
doxorubicin (0.5 lM) for 72 h and viability was assessed by MTS assay. (E) Endogenous NUPR1 in MCF10AT cells was silenced by RNA interference. 187-3, -6, -9 denote stable
clones that are silenced for NUPR1 using shRNA187. EV denotes empty vector transfectants and SC denotes cells transfected with a non-targeting control shRNA. Loss of
NUPR1 is accompanied by a notable change in the levels of p21. (F). Abrogating endogenous NUPR1 increased the sensitivity of the cells to doxorubicin (0.5 lM for 72 h)
(⁄p < 0.05). (G) Relative to the MCF10AT cells transfected with empty vector (EV) and non-targeting control shRNA (SC), the NUPR1-silenced cells (shNUPR1) show nuclear
localization of p21 (FITC) when assessed by immunocytochemistry. DAPI serves to label the nuclei.
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overexpressing cells also showed an overall increase in BCL-xL lev-
els. However, the deactivated phosphorylated 62-serine form of
BCL-xL was barely detectable in NUPR1-expressing cells in com-
parison to vector control cells [28]. We did not detect any change
in the P-Ser-146-p21 levels. Phosphorylation of p21 at Ser 146
and/or Thr 145 is associated with cytoplasmic localization of p21
and lead to activated Bcl-xL. In order to assess a role for activated
PI-3-K/Akt in mediating phosphorylation of p21 at the Thr145 and/
or Ser146 residues we treated the vector control and NUPR1-
expressing cells with inhibitors of Akt (Akt Inhibitor IV) and PI-3-
kinase (wortmannin). We also assessed a role for IKK (NF-jB
signaling) using BMS-34551. Treatment with an Akt inhibitor
resulted in reduced levels of activated p-Ser-473-Akt with concom-
itantly decreased levels of p-Thr-145-p21. This was accompanied
by an increase in p-Ser-62-Bcl-xL, indicating an increase in the cel-
lular pools of inactive Bcl-XL (Fig. 3 A& B). Notably, while inhibition
of NF-jB signaling had no impact on the total cellular pool of p21,
inhibition of PI-3-kinase and Akt caused a drastic decrease in the
levels of total p21. While not completely resolved, there are a cou-
ple of reports documenting a role for Akt in stabilizing p21 [29,30];
and the withdrawal of or interference in Akt signaling destabilizes
p21 by targeting it for proteasomal degradation [30]. Inhibition of
IKK with BMS-345541 did not result in any notable change in the
levels of phosphorylated Akt or p-Thr-145-p21. There was a mini-
mal change in the levels of p-Ser-62-Bcl-xL. Inhibition of PI-3-ki-
nase using wortmannin greatly impacted the activation of Akt asseen by a complete absence of p-Ser-473-Akt in the treated
NUPR1-expressing cells. There was a simultaneous profound
reduction in the p-Thr-145-p21 levels. Surprisingly, the pools of
p-Ser-62-Bcl-xL remained low in the NUPR1-expressing cells de-
spite wortmannin treatment. The 146-Serine residue of p21 was
not affected by any variables imposed in this study. Taken to-
gether, these results support our claims that NUPR1 mediates cyto-
plasmic localization of p21 by phosphorylating its nuclear
localization signal in a PI-3 Kinase/Akt dependent manner. In addi-
tion, this correlated with subsequent activation of anti-apoptotic
Bcl-xL.
4.4. Inhibition of Akt and PI-3K sensitizes NUPR1-expressing cells to
doxorubicin
In order to understand the determinative role of NUPR1-in-
duced PI-3-K/Akt-mediated phosphorylation and cytoplasmic
localization of p21 with the chemoresistance properties of the
cells, we assessed the response of the cells to doxorubicin when
co-treated with inhibitors of Akt, PI-3-K and IKK. As seen in
Fig. 4A and B, while inhibition of Akt and PI-3-kinase restored
the sensitivity of the NUPR1-expressing cells to doxorubicin, the
NUPR1-expressing cells remained resistant to doxorubicin even
in presence of the IKK inhibitor, indicating that the chemoresis-
tance imparted by NUPR1 is independent of the NF-jB pathway
(Fig. 4C). Pre-treatment with any of the inhibitors did not impact
the response to doxorubicin (data not shown).
Fig. 2. Blocking PI3K/Akt signaling reverses NUPR1-mediated p21 cytoplasmic localization in SUM159 cells. SUM159 cells were plated on coverslips and treated for 24 h with
the indicated inhibitor (Akt Inhibitor IV l lM, or Wortmannin l lM or BMS-345541, l lM). Cells were ﬁxed and stained as indicated in Methods and Materials. Images
acquired at 40 magniﬁcation. NUPR1 overexpressing cells displayed predominantly cytoplasmic localization of p21, which was reversed by both Akt Inhibitor IV and
Wortmannin treatment. Representative images are shown. The ratio of nuclear:cytoplasmic signal of p21 was determined from these images. Mean intensity of p21 staining
was determined for each cell in both the cell nucleus and the whole cell. Cytoplasmic intensity was determined indirectly by subtracting the summed nuclear intensity from
the summed cellular intensity and controlling for cellular volume. A ratio was then taken for each cell comparing the mean intensity of the cell nucleus to the mean intensity
of the cytoplasm. p21 localization becomes similar after treatment with Wortmannin and Akt Inhibitor IV.
Fig. 3. NUPR1 leads to phosphorylation of p21 via intermediates PI-3 Kinase and Akt and is correlated with increased levels of hypophosphorylated BCL-xL. (A) NUPR1
overexpressing SUM159 cells displayed increased total Akt and the active phosphorylated form of Akt (phospho-473-Serine Akt). These cells also showed increased
phosphorylation of p21 at the 145-Threonine residue but not at the 146-Serine residue. Treatment for 2 h with Akt and PI-3 Kinase inhibitors (Akt Inhibitor IV and
Wortmannin, respectively) reversed the phosphorylation status of both Akt and p21. Inhibition of IKK using BMS-345541 did not impact the phosphorylation of p21. NUPR1
overexpressing SUM159 cells also demonstrated increased levels of BCL-xL but decreased phosphorylated 62-Serine signal. Cells treated with Akt Inhibitor or Wortmannin for
24 h showed an increase in the levels of phosphorylated BCL-xL. (B) Densiometric analysis of p21 phosphorylation status reveals decrease in p21 phosphorylation of the 145-
Threonine residue after treating NUPR1 overexpressing cells with Akt Inhibitor IV and Wortmannin, but not IKK inhibitor. The levels of Bcl-xL phosphorylation (indicating
inactive Bcl-xL) is increased when the NUPR1-expressing cells are treated with Akt inhibitor relative to untreated cells. Wortmannin or BMS-345541 treatment does not
impact Bcl-xL phosphorylation.
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Fig. 4. NUPR1 mediates chemoresponsiveness via PI-3-K/Akt. SUM159 cells transfected with empty vector or NUPR1 were treated with doxorubicin (0.5 lM) and/or Akt
inhibitor IV (1 lM) or wortmannin (1 lM) or IKK inhibitor (1 lM) and cell viability was assessed 24 h later by MTS assay. The NUPR1 cells demonstrated increased
proliferation in culture (untreated). While the inhibitors alone did not impact cell viability, when co-treated with (A) Akt inhibitor or (B) wortmannin, the NUPR1-expressing
cells regained sensitivity to doxorubicin. (C) Inhibition of IKK did not impact cellular response to doxorubicin (even when higher concentrations of the IKK inhibitor were
used; data not shown).
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NUPR1 was ﬁrst identiﬁed as a protein physiologically involved
in the cellular stress response, promoting regeneration and cellular
growth [31]. NUPR1 functions in the nucleus where it serves as a
co-factor for transcription factors such as p53 [9] and estrogen
receptor-b [32]. Since NUPR1 is a stress molecule that might be
upregulated in actual in vivo conditions, where the tumor cells un-
dergo selection pressure, stress from the surrounding cells and
from the host’s defense mechanisms may play critical roles in
inﬂuencing the activity of NUPR1. The potential of NUPR1 in mak-
ing cancer cells resistant to the effects of conventional chemother-
apeutic agents is suggested by two independent studies examining
the effects of NUPR1 expression in pancreatic [33] and breast can-
cer [9]. Gemcitabine, the drug of choice for pancreatic cancer, was
found to target NUPR1. Gemcitabine resistant pancreatic cancer
cells devoid of NUPR1 (NUPR1/) were more prone to apoptosis
than their wild type counterparts, and gemcitabine-induced apop-
tosis mainly resulted from the inhibition of the constitutive antiap-
optotic activity of NUPR1 [3].
Alternatively, named as cyclin-dependent kinase inhibitor-IA
(CDKN1A), CDK-interacting protein 1 (CIP1) and wild-type p53-
activated fragment 1 (WAF1), p21 is a protein possessing duality
in the regulation of cancer behavior. The nuclear form of p21
mainly executes its tumor suppressing function by binding to
CDK complexes, inhibiting the activity of cyclin-dependent ki-
nases, such as, Cdk2, Cdk3, Cdk4 and Cdk6, leading to cell growth
arrest [14]. In contrast, the cytoplasmic form of p21 complexes
with and inactivates pro-apoptotic proteins such as caspase-3
[12] and ASK-1 [13,34]. This oncogenic function of p21 has also
been validated by clinical evidence. Higher expression of cytoplas-
mic p21 has been veriﬁed as a factor of poor prognosis in human
primary breast carcinomas [23,35]. Moreover, resistance to che-
motherapeutic drugs may result from accumulation of cytoplas-
mic p21, as paclitaxel could increase cytoplasmic p21, and
reverse the cell cycle inhibitory effect of p21 [25,26]. Thus, cellu-
lar localization plays a critical role to determine the function of
p21, i.e. nuclear p21, as a cell cycle inhibitor, represses cell
growth; cytoplasmic p21, as an anti-apoptotic factor, enhances
cell survival. Phosphorylation of p21 at Ser 146 and/or Thr 145
is associated with cytoplasmic localization of p21 [22]. Activated
Akt phosphorylates p21 at Ser 146 and stabilizes p21; phosphor-
ylation of p21 at the Thr 145 position makes p21 a positive
modulator of cell survival and proliferation. Speciﬁcally,
phosphorylated p21 does not inhibit cyclin E-CDK2 but instead,
promotes the binding and assembly and activation of the cyclin
D1-CDK4 complex, which is a critical mediator of G1-S progres-
sion, acting epistatic to and inhibiting p27. Phosphorylation ofp21 at Thr145 releases PCNA from p21 binding and resultant inhi-
bition. This release allows for elevated p21 levels to exist in cells
without inhibiting the cell’s ability to progress through S phase
[30,36]. As such, phosphorylation of p21 at these two critical res-
idues not only alters its sub-cellular localization, but also inter-
feres in the growth-restrictive properties of p21 so profoundly,
making it a pro-survival molecule.
We have previously shown that p53 and p300 are required for
NUPR1 mediated up-regulation of p21 [9]. Mutations in p53 are
seen in about 30% of breast cancers. Triple-negative basal-like
breast cancers account for 15% of breast cancers and have an in-
creased frequency of p53 mutations. Mutant p53 status is a
strongly unfavorable prognostic indicator in these patients for
overall survival and response to anthracycline-containing therapy.
Inﬂammatory breast cancer (T4d in the TNM classiﬁcation) has a
particularly aggressive behavior and poor prognosis, and muta-
tions in p53 are more frequent (50%) in inﬂammatory than in
non-inﬂammatory breast cancer (20–30%) [37]. The SUM159PT cell
line, derived from inﬂammatory breast cancer contains a p53 loss
of function missense mutation [18], and is triple-negative for ER,
PR, and HER2/Neu [38]. Thus, it presents a unique system to study
the role of NUPR1 in chemoresistance. In these cells NUPR1 expres-
sion did not result in an appreciable increase in p21, but rather
resulted in altered localization of p21. Thus, the regulation of
sub-cellular localization of p21 mediated by Akt is, from the per-
spective of NUPR1-induced chemoresistance, a novel ﬁnding. Akt
has been well studied for its role in inhibiting apoptosis and pro-
moting cell survival. The PI-3K-Akt pathway has been linked to
resistance to a variety of chemotherapeutics, such as gemcitabine,
irinotecan, etoposide, and Taxol [39–43]. Hyperphosphorylation of
Akt has also been linked to poor prognosis in a variety of cancers
[44]. Our results show that p21 that is phosphorylated by Akt is
unable to carry out its tumor suppressive functions, and instead
causes activation of BCL-xL available in the cellular pool to com-
plex with and de-activate pro-apoptotic Bax. NUPR1 overexpres-
sion increases cellular proliferation, while removing necessary
cell cycle checkpoints [9], and our ﬁndings elucidate a NUPR1-
PI-3-K/Akt-phospho-p21 axis that enhances chemoresistance in
breast cancer cells. Various PI-3-K/Akt inhibitors are in clinical tri-
als. It is possible that the use of such inhibitors may help restore
chemosensitivity in patients whose tumors show upregulated
NUPR1 expression, thereby expanding the scope of the treatment.
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